Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

LMP2-Specific IL12-secreting TCR-T Cell therapy - TCRCure Biotech

Next Previous
Drug Profile

LMP2-Specific IL12-secreting TCR-T Cell therapy - TCRCure Biotech

Alternative Names: EBV TCR-T - TCRCure Biotech; LMBP2-specific TCR-T cells - TCRCure Biotech

Latest Information Update: 30 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TCRCure Biotech
  • Developer TCRCure Biopharma
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Interleukin 2 stimulants; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Nasopharyngeal cancer

Most Recent Events

  • 22 Oct 2024 TCRCure Biotech reinitiates a phase I/II trial in Nasopharyngeal cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in China (Parenteral, Infusion) (NCT04509726)
  • 02 Oct 2024 TCRCure Biotech suspends phase I/II trial in Nasopharyngeal cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in China (Parenteral, Infusion) due to scheduled pause (NCT04509726)
  • 01 Mar 2023 Phase-I/II clinical trials in Nasopharyngeal cancer (Metastatic disease, Second-line therapy or greater, Recurrent) in China (Infusion) (NCT04509726)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top